BACKGROUND: Survival bias is the phenomenon by which individuals are excluded from analysis of a trait because of mortality related to the expression of that trait. In genetic association studies, variants increasing risk for disease onset as well as risk of disease-related mortality (lethality) could be difficult to detect in genetic association case-control designs, possibly leading to underestimation of a variant's effect on disease risk. METHODS AND RESULTS: We modeled cohorts for 3 diseases of high lethality (intracerebral hemorrhage, ischemic stroke, and myocardial infarction) using existing longitudinal data. Based on these models, we simulated case-control genetic association studies for genetic risk factors of varying effect sizes, lethality, and minor allele frequencies. For each disease, erosion of detected effect size was larger for case-control studies of individuals of advanced age (age >75 years) and/or variants with very high event-associated lethality (genotype relative risk for event-related death >2.0). We found that survival bias results in no more than 20% effect size erosion for cohorts with mean age <75 years, even for variants that double lethality risk. Furthermore, we found that increasing effect size erosion was accompanied by depletion of minor allele frequencies in the case population, yielding a "signature" of the presence of survival bias. CONCLUSIONS: Our simulation provides formulas to allow estimation of effect size erosion given a variant's odds ratio of disease, odds ratio of lethality, and minor allele frequencies. These formulas will add precision to power calculation and replication efforts for case-control genetic studies. Our approach requires validation using prospective data.
BACKGROUND: Survival bias is the phenomenon by which individuals are excluded from analysis of a trait because of mortality related to the expression of that trait. In genetic association studies, variants increasing risk for disease onset as well as risk of disease-related mortality (lethality) could be difficult to detect in genetic association case-control designs, possibly leading to underestimation of a variant's effect on disease risk. METHODS AND RESULTS: We modeled cohorts for 3 diseases of high lethality (intracerebral hemorrhage, ischemic stroke, and myocardial infarction) using existing longitudinal data. Based on these models, we simulated case-control genetic association studies for genetic risk factors of varying effect sizes, lethality, and minor allele frequencies. For each disease, erosion of detected effect size was larger for case-control studies of individuals of advanced age (age >75 years) and/or variants with very high event-associated lethality (genotype relative risk for event-related death >2.0). We found that survival bias results in no more than 20% effect size erosion for cohorts with mean age <75 years, even for variants that double lethality risk. Furthermore, we found that increasing effect size erosion was accompanied by depletion of minor allele frequencies in the case population, yielding a "signature" of the presence of survival bias. CONCLUSIONS: Our simulation provides formulas to allow estimation of effect size erosion given a variant's odds ratio of disease, odds ratio of lethality, and minor allele frequencies. These formulas will add precision to power calculation and replication efforts for case-control genetic studies. Our approach requires validation using prospective data.
Authors: J Nadelmann; W H Frishman; W L Ooi; D Tepper; S Greenberg; H Guzik; E J Lazar; M Heiman; M Aronson Journal: Am J Cardiol Date: 1990-09-01 Impact factor: 2.778
Authors: M Hollander; P J Koudstaal; M L Bots; D E Grobbee; A Hofman; M M B Breteler Journal: J Neurol Neurosurg Psychiatry Date: 2003-03 Impact factor: 10.154
Authors: R Cooper; J Cutler; P Desvigne-Nickens; S P Fortmann; L Friedman; R Havlik; G Hogelin; J Marler; P McGovern; G Morosco; L Mosca; T Pearson; J Stamler; D Stryer; T Thom Journal: Circulation Date: 2000-12-19 Impact factor: 29.690
Authors: Ann I Scher; Gudny Eiriksdottir; Melissa Garcia; Preethy Feit; Albert V Smith; Tamara B Harris; Kathryn A Roecklein; Larus S Gudmundsson; Vilmundur Gudnason; Lenore J Launer Journal: Cephalalgia Date: 2012-12-10 Impact factor: 6.292
Authors: Chung-Jung Chiu; Yvette P Conley; Michael B Gorin; Gary Gensler; Chao-Qiang Lai; Fu Shang; Allen Taylor Journal: Invest Ophthalmol Vis Sci Date: 2011-11-25 Impact factor: 4.799
Authors: Javier G Blanco; Can-Lan Sun; Wendy Landier; Lu Chen; Diego Esparza-Duran; Wendy Leisenring; Allison Mays; Debra L Friedman; Jill P Ginsberg; Melissa M Hudson; Joseph P Neglia; Kevin C Oeffinger; A Kim Ritchey; Doojduen Villaluna; Mary V Relling; Smita Bhatia Journal: J Clin Oncol Date: 2011-11-28 Impact factor: 44.544
Authors: Guido J Falcone; Alessandro Biffi; William J Devan; Jeremiasz M Jagiella; Helena Schmidt; Brett Kissela; Björn M Hansen; Jordi Jimenez-Conde; Eva Giralt-Steinhauer; Roberto Elosua; Elisa Cuadrado-Godia; Carolina Soriano; Alison M Ayres; Kristin Schwab; Joanna Pera; Andrzej Urbanik; Natalia S Rost; Joshua N Goldstein; Anand Viswanathan; Alexander Pichler; Christian Enzinger; Bo Norrving; David L Tirschwell; Magdy Selim; Devin L Brown; Scott L Silliman; Bradford B Worrall; James F Meschia; Chelsea S Kidwell; Joan Montaner; Israel Fernandez-Cadenas; Pilar Delgado; Joseph P Broderick; Steven M Greenberg; Jaume Roquer; Arne Lindgren; Agnieszka Slowik; Reinhold Schmidt; Matthew L Flaherty; Dawn O Kleindorfer; Carl D Langefeld; Daniel Woo; Jonathan Rosand Journal: Stroke Date: 2012-08-28 Impact factor: 7.914
Authors: Guido J Falcone; Alessandro Biffi; William J Devan; H Bart Brouwers; Christopher D Anderson; Valerie Valant; Alison M Ayres; Kristin Schwab; Natalia S Rost; Joshua N Goldstein; Anand Viswanathan; Steven M Greenberg; Magdy Selim; James F Meschia; Devin L Brown; Bradford B Worrall; Scott L Silliman; David L Tirschwell; Jonathan Rosand Journal: Stroke Date: 2013-01-15 Impact factor: 7.914